Xin Lang Cai Jing·2026-01-27 08:35Group 1 - The core message highlights the significant antiviral activity of the oral nucleoside drug VV116 against the Nipah virus, providing new hope for the prevention and treatment of this high-mortality infectious disease [1][2] - VV116, also known as Dromidavir, has previously been approved for COVID-19 treatment in Uzbekistan and China, with its development for Nipah virus treatment being closely monitored by the companies involved, including Wangshan Wangshui and Junshi Biosciences [1] - Clinical pre-data indicates VV116's potential for treating Nipah virus infections, with plans to initiate clinical trials in response to public health needs due to the virus's high fatality rate and lack of vaccines or effective treatments [1] Group 2 - The World Health Organization describes the Nipah virus as a zoonotic virus with a human fatality rate typically exceeding 40%, with no licensed vaccines or specific treatments available [2] - Recent reports indicate a small outbreak of Nipah virus in West Bengal, India, with confirmed cases rising to five, highlighting the virus's potential for localized high-fatality outbreaks [2] - Despite the outbreak in India, there have been no reported human cases of Nipah virus infection in mainland China, suggesting a need for vigilance and good hygiene practices without causing public panic [3] Group 3 - As of January 27, Wangshan Wangshui's stock rose by 10.90%, while Junshi Biosciences saw an increase of 7.96% in A-shares and 1.35% in H-shares, reflecting market optimism following the announcement of VV116's potential [4]